All articles by William Newton
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Pharma, patient advocates clash over Inflation Reduction Act
Pharma reps and patient advocates debated the effect of the IRA on drug pricing and innovation at a Financial Times summit panel.
WHO declares end of Covid-19 public health emergency
The WHO ended the public health emergency for Covid-19 as the pharma industry continues to invest heavily in antiviral drug development.
Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies
It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?
Can Relmada’s fast-acting pill for major depressive disorder compete in a crowded market?
Relmada’s investigational pill for major depressive disorder (MDD) could face tough competition with entrenched generic SSRIs and novices like J&J’s Spravato.
An oral pill for alcohol abuse vies to enter a quickly evolving market
Adial Pharmaceuticals CEO William Stilley discusses the challenges of bringing an alcohol abuse disorder therapy to market.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
An uphill battle for insulin pricing reform as copay cap bill enters US Senate
Congress has renewed its longstanding push for insulin pricing reform with the Affordable Insulin Now Act, but will it be enough?
Insulin pricing: could an e-commerce approach cut costs?
An e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.
Amylyx AdCom: panelists narrowly vote against FDA approval
Some AdCom panelists cited concerns with Amylyx’s trial design, while others pointed to positive data and the high unmet need in ALS.
Navigating distribution challenges for rare disease drugs
On Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.
Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
A close FDA committee vote to authorize molnupiravir indicates that mAbs could still be favored for Covid-19 when available.